LIGHT

Treatment tested

• Antithymocyte
• Cyclophosphamide anhydrous

Inclusion: - Age between 18 and 50 Clinically and laboratory definite RRMS or RP EDSS score between 3 and 6.5 Documented rapid progression over the previous year despite conventional therapies immunomodulating and immunosuppressive treatments, see below; progression is defined as a worsening of 1 or more EDSS points between 3 and 6 or 0.5 or more between 6 and 6.5 or at least three relapses in the previous year also without progression of the disease despite conventional therapies immunomodulating and immunosuppressive treatments, see below Presence of at least 1 enhancing area on brain MRI using a triple dose TD of Gd Previous treatment with immunomodulating drugs interferon beta or glatiramer acetate without efficacy Previous treatment with immunosuppressive drugs Mitoxantrone or CY at standard dosage without efficacy Acceptance of using a valid birth control Exclusion: Primary progressive or Secondary Progressive MS Relapse in the last 30 days Previous treatment with TBI or TLI Treatment with Interferons, Cop1 or steroids in the last month Treatment with CY, Mitoxantrone, Aza, or other immunosuppressant in the last 3 months Concomitant diseases of lungs, kidneys, liver, heart, endocrine or neurological systems, Infectious illnesses, Psychiatric disturbances Left ventricular ejection fraction 50 , unexplained ECG abnormalities History of recurrent urinary tract infections or respiratory infections Pregnancy, breast feedings, patient s non compliance to use birth control methods Contraindications for MRI

The objective is therefore the search of a new light immunoablative regimen, with a better safety profile than BEAM but with a similar efficacy.